Gossamer Bio, Inc. Common Stock
GOSSGossamer Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies primarily for rare, serious, and underserved diseases. The company's pipeline includes innovative treatments in areas such as immunology, inflammation, and oncology, aiming to address unmet medical needs through novel scientific approaches.
Company News
Respira Therapeutics has granted Gossamer Bio an option to acquire the company, focusing on developing RT234, an investigational as-needed treatment for pulmonary hypertension. The agreement includes stock issuance and potential milestone payments.
Gossamer Bio has entered an option agreement to acquire Respira Therapeutics and its lead candidate RT234, an inhaled vardenafil therapy for pulmonary hypertension, with potential to expand its pulmonary hypertension treatment portfolio.
The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market is expected to grow significantly between 2025-2034, driven by improved diagnostic techniques, disease recognition, and emerging therapies targeting functional improvement and disease progression.
The article discusses the evolving landscape of rare cardiovascular diseases, including Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy. It highlights the challenges in diagnosis and treatment, as well as the growing market size and pipeline of new therapies for these conditions.
XOMA Royalty Corporation has acquired Pulmokine Inc. for $20 million, adding the royalty and milestone interest in seralutinib, a Phase 3 asset being studied for pulmonary arterial hypertension, to its portfolio.
